Key Takeaways
- The DEA registered over 900 medical marijuana dispensaries across seven states as part of the transition to Schedule III.
- New guidance requires dispensaries to verify trading partners and only engage with Timely Applicants or DEA registrants by November 29.
- The DEA denied registration to a Minnesota dispensary due to its dual-purpose license, conflicting with federal regulations.
- Minnesota’s cannabis office reaffirmed that the DEA order doesn’t affect state law or patient access to medical cannabis.
- Medical marijuana businesses should ensure compliance with DEA’s requirements and review trading partners before the upcoming deadline.
On Friday October 30th, the DEA issued federal registrations to more than 900 medical marijuana dispensaries in seven states, a major step in implementing marijuana’s move to Schedule III.
A couple other announcements also dropped that same Friday, and together they show how DEA plans to handle medical marijuana registration under rescheduling: one grants access, one sets rules for who dispensaries can buy from and sell to, and one draws a hard line by denying registration to a Minnesota dispensary over the state’s dual medical and recreational licensing structure.
Which States Got DEA Registered Medical Marijuana Dispensaries?
Attorney General Todd Blanche announced that DEA has granted federal registration and protections to more than 900 medical marijuana dispensaries. The businesses are located in Alabama, Florida, Mississippi, South Dakota, Texas, Virginia and West Virginia, according to the DOJ press release. DOJ described the registrations as “the first phase of implementing” marijuana rescheduling.
This first batch covers businesses that applied during a 60-day window set up for expedited consideration. Blanche said the move will “help ensure broader access to chronic pain treatment and the safety of the American people,” while adding that DOJ “will continue prosecuting illegal marijuana trafficking and related criminal activity in accordance with federal law.”
DOJ was clear that a state license doesn’t automatically translate to federal approval. Registered dispensaries now answer to federal requirements covering security, recordkeeping, inventory controls and other safeguards tied to handling controlled substances. DEA separately disclosed that nearly 7,000 medical marijuana businesses have applied for federal protections so far, and the agency is now reviewing applications from manufacturers and distributors too, a process that includes facility inspections and quota determinations.
This all traces back to April 2026, when Blanche ordered marijuana products tied to a state medical license moved from Schedule I to Schedule III of the Controlled Substances Act, alongside FDA-approved marijuana products. A separate DEA hearing weighing broader, non-medical rescheduling recently wrapped up testimony.
What Does DEA’s New Supplier Guidance Require?
Alongside the registration news, DEA published four pages of guidance telling medical marijuana businesses to clean up their supply chains. Companies seeking or holding federal registration have until November 29 to make sure they’re only dealing with other “Timely Applicants” or DEA registrants.
The guidance doesn’t mince words about the stakes: “If a Timely Applicant or DEA registrant engages in schedule III medical marijuana activities with someone other than a Timely Applicant or DEA registrant, such conduct could be potential grounds for denial of a Timely Applicant’s application or revocation of a certificate of registration, respectively.”
DEA laid out specific due diligence steps businesses should follow. Dispensers need to collect a trading partner’s “Marijuana Dispensary Information Submission” confirmation and verify the document control number through the DEA Diversion Control Website. Manufacturers and distributors face a similar check using their own submission confirmation. For anyone already holding a DEA registration, businesses should obtain a copy of that certificate. State licenses need to be verified as active too, and all of this due diligence needs to be documented and kept on file.
There’s some breathing room built in. Businesses can keep selling existing inventory acquired before the guidance came out, even if it originally came from a non-qualifying source. And DEA said it won’t penalize sending small quantities to a non-DEA-registered lab in the same state for testing, as long as no DEA-registered lab exists anywhere in the country, or state law blocks sending samples out of state and none are registered locally. That exception covers sending product to labs, not receiving marijuana back from one that isn’t registered.
Why Did DEA Deny a Minnesota Dispensary’s Registration?
Not every applicant is getting through. DEA sent an order to show cause to In-Dispensary LLC, a Minneapolis business, denying its pending application. The order, signed by Cheri Oz, assistant administrator of DEA’s Diversion Control Division, says the agency “cannot permit any applicant operating under” Minnesota’s cannabis law to receive federal registration.
The main issue is Minnesota’s dual-purpose license, which lets a single business sell both medical and recreational marijuana. DEA said this structure “falls outside the recently promulgated definition of ‘state medical marijuana license'” and conflicts with the Controlled Substances Act and US obligations under the Single Convention on Narcotic Drugs, a 1961 international treaty. The order also argues that dispensing marijuana for non-medical use under the same license as medical use counts as diversion by definition, something the CSA’s registration framework is designed to prevent.
DEA cited two more problems with Minnesota’s law. The state allows military veterans to access medical cannabis with only a veteran ID and a signed attestation of a qualifying condition, skipping the written physician certification DEA says federal rules require. Minnesota also permits dispensaries to sell what DEA called “synthetic marijuana products,” referring to hemp-derived cannabinoids.
In-Dispensary has 30 days to request a hearing or submit a corrective action plan. A hearing date of January 19, 2027 is listed if one is requested. The Star Tribune first reported the order, noting that Mark Eide, the dispensary’s owner, said DEA agents delivered the notice to him in person.
You can see the full letter here contributed by Matt DeLong.
How Is Minnesota Responding to the DEA Order?
The Minnesota Office of Cannabis Management told the Star Tribune that the order “does not impact the state law that authorizes Minnesota’s medical cannabis and adult-use cannabis programs” and that “medical cannabis remains available to patients in the state.” The agency framed its regulatory approach as one that prioritizes public health, consumer confidence and market integrity.
It’s worth noting that DEA’s order specifically targets Minnesota’s licensing structure rather than issuing a blanket rule against every state with dual licensing. All seven states that received registrations in this first batch only permit medical cannabis, with one exception. Virginia has passed legislation legalizing adult-use sales but hasn’t started licensing recreational businesses yet, so it hasn’t triggered the same conflict.
Businesses in states allowing both medical and recreational licensing under one system may end up missing out on the benefits tied to rescheduling. It also remains unclear how adult-use businesses in any state could eventually qualify for DEA registration if broader, non-medical rescheduling moves forward, given the agency’s stance on certification requirements.
What Should Medical Marijuana Businesses Do Next?
For businesses that already hold a state medical marijuana license and applied within the 60-day window, the priority right now is reviewing trading partners against DEA’s November 29 deadline. That means pulling documentation, verifying DCNs and license status, and keeping records of every check performed.
For businesses in states with dual medical and recreational licensing structures, the Minnesota case offers a preview of the kind of scrutiny DEA may apply elsewhere, though the agency hasn’t issued a rule covering every such state at once. Businesses with questions about how their state’s regulatory framework lines up with DEA’s definitions may want to consult legal counsel familiar with cannabis compliance before the supply chain deadline arrives.
Frequently Asked Questions
As of the October 30, 2026 announcement, DEA registered more than 900 dispensaries in Alabama, Florida, Mississippi, South Dakota, Texas, Virginia and West Virginia. DEA said this is the first phase of a phased registration process and that applications from businesses in other states remain under review.
DEA’s guidance instructs businesses to request a trading partner’s DEA certificate of registration, or, for pending applicants, their submission confirmation and document control number, which can be verified through the DEA Diversion Control Website. Businesses should also confirm the trading partner’s state license is active and keep records of this due diligence.
DEA denied In-Dispensary LLC’s application because Minnesota’s dual-purpose license allows the same business to sell both medical and recreational marijuana, which DEA said falls outside its definition of a state medical marijuana license and conflicts with federal law. DEA also cited Minnesota’s veteran self-certification process and its allowance of hemp-derived cannabinoid sales.
Based on DEA’s order to the Minnesota dispensary, businesses operating under a dual-purpose license structure that permits both medical and non-medical sales under one license may face denial. DEA’s order addressed Minnesota’s law specifically, and Marijuana Moment reported that businesses in similar dual-license states may miss out on rescheduling benefits.
DEA’s supply chain guidance gives Timely Applicants and registrants until November 29, 2026 to confirm that they are only engaging in schedule III medical marijuana activities with other Timely Applicants or DEA registrants, and to adjust their supply chains accordingly.
